This is a non-core endpoint: only basic statistics are computed.
See these related core endpoints for full statistics:
Giant cell arteritis with polymyalgia rheumatica
DOID EFO MESH SNOMED Endpoint Browser
GIANT_CELL_TEMP_ARTERITIS
polymyalgia rheumatica: Polymyalgia rheumatica is a common inflammatory condition that often affects people over the age of 50 years. Characteristic symptoms are shoulder and hip girdle pain and prolonged morning stiffness. Markers of inflammation are often elevated.
Endpoint definition
↥
FinnGen phenotype data
429209 individuals
Apply sex-specific rule None
429209
Check conditions None
429209
Check pre-conditions, main-only, mode, registry filters
2 out of 7 registries used, show all original rules.
979
Check minimum number of events None
979
Include endpoints None
979
Remove individuals based on genotype QC
958
GIANT_CELL_TEMP_ARTERITIS
Control definitions
Control exclude
NECROVASC_FG
Extra metadata
First used in FinnGen datafreeze
DF2
Parent code in ICD-10
M31
Name in latin
Arteritis gigantocellularis cum polymyalgia reumatica
Show upset plot detailing case counts by codes
Or the full data table
Similar endpoints
↥List of similar endpoints to
Giant cell arteritis with polymyalgia rheumatica
based on the number of shared cases.
Broader endpoints:
- Temporal arteritis
- Giant cell arteritis
- Other necrotizing vasculopathies (FG)
- Other necrotizing vasculopathies
- Systemic connective tissue disorders
Narrower endpoints:
Summary Statistics
↥Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 958 | 584 | 374 |
| Unadjusted prevalence (%) | 0.23 | 0.25 | 0.21 |
| Mean age at first event (years) | 68.26 | 67.51 | 69.44 |
Mortality
Not a core endpoint, no data to show.
Age distribution of first events
Year distribution of first events
Cumulative Incidence
Not a core endpoint, no data to show.
Correlations
↥
Index endpoint: GIANT_CELL_TEMP_ARTERITIS – Giant cell arteritis with polymyalgia rheumatica
GWS hits:
Survival analyses between endpoints
↥Not a core endpoint, no data to show.
Drugs most likely to be purchased after Giant cell arteritis with polymyalgia rheumatica
↥Endpoint not on priority list, no data to show.